Regional Observatory on Metabolic Syndrome- LAZIO

The aim of the study, is to assess the prevalence of Metabolic Syndrome in Italy on a regional basis, defined according to NCEP/ATPIII Guidelines criteria.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metabolic Syndrome Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Rieti, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

lipid profile in the last year
Signed informed consent

Exclusion criteria

Subjects with serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's successful participation in the study
Pregnancy or breast feeding
Subject who are unwilling or unable to provide the informed consent

Treatment and study plan

Primary outcomes

Prevalence of Metabolic Syndrome in Primary Care Population.

Time frame: At Visit

Secondary outcomes

Concomitant presence of other CV risk factors.

Time frame: At Visit

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Regional Observatory on Metabolic Syndrome in Italy- LAZIO

Acronym: ORSA

Important dates

Study start: 2007
Primary completion: 2008
Study completion: 2008
First posted: Jun 3, 2008
Registry last updated: Dec 3, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed